Metsera Inc
NASDAQ:MTSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Metsera Inc
NASDAQ:MTSR
|
US |
|
Pidilite Industries Ltd
NSE:PIDILITIND
|
IN |
|
Duta Intidaya Tbk PT
IDX:DAYA
|
ID |
|
R
|
Raspadskaya PAO
MOEX:RASP
|
RU |
|
Suofeiya Home Collection Co Ltd
SZSE:002572
|
CN |
|
S
|
Sangji Caelum Inc
KOSDAQ:042940
|
KR |
|
Marimekko Oyj
OTC:MKKOF
|
FI |
|
A
|
Asuransi Maximus Graha Persada Tbk PT
IDX:ASMI
|
ID |
|
First Robinson Financial Cororation
OTC:FRFC
|
US |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
US |
|
First Guaranty Bancshares Inc
NASDAQ:FGBI
|
US |
|
A
|
Absa Group Ltd
JSE:ABG
|
ZA |
|
G
|
Gabia Inc
KOSDAQ:079940
|
KR |
|
Hyliion Holdings Corp
NYSE:HYLN
|
US |
|
B
|
BNP Paribas SA
XETRA:BNP
|
FR |
|
Recharge Metals Ltd
ASX:REC
|
AU |
|
T
|
TK Chemical Corp
KOSDAQ:104480
|
KR |
Metsera Inc
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 57 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 57 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
